Dinesh Khanna1, Shikha Mittoo2, Rohit Aggarwal2, Susanna M Proudman2, Nicola Dalbeth2, Eric L Matteson2, Kevin Brown2, Kevin Flaherty2, Athol U Wells2, James R Seibold2, Vibeke Strand2. 1. From the Department of Internal Medicine, Division of Rheumatology, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, Michigan, USA; University of Toronto, Toronto, Ontario, Canada; University of Pittsburgh, Pittsburgh, Pennsylvania, USA; Royal Adelaide Hospital and University of Adelaide, Adelaide, Australia; University of Auckland, Auckland, New Zealand; Mayo Clinic, Rochester, Minnesota; National Jewish Hospital, Denver, Colorado, USA; Royal Brompton Hospital and National Heart and Lung Institute, London, UK; Scleroderma Research Consultants, Litchfield, Connecticut; Vibeke Strand, MD, Stanford University, Palo Alto, California, USA.D. Khanna, MD, MSc, Associate Professor of Medicine, Director, University of Michigan Scleroderma Program, University of Michigan; S. Mittoo, MD, MHS, University of Toronto; R. Aggarwal, MD, MS, Assistant Professor of Medicine, University of Pittsburgh; S.M. Proudman, MBBS, Royal Adelaide Hospital and Associate Professor Discipline of Medicine, University of Adelaide; N. Dalbeth, MD, FRACP, University of Auckland; E.L. Matteson, MD, Mayo Clinic; K. Brown, MD, National Jewish Hospital; K. Flahery, MD, MSc, Professor of Medicine, University of Michigan; A.U. Wells, MD, Royal Brompton Hospital and National Heart and Lung Institute; J.R. Seibold, MD, Scleroderma Research Consultants; V. Strand, MD, Stanford University. khannad@umich.edu. 2. From the Department of Internal Medicine, Division of Rheumatology, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, Michigan, USA; University of Toronto, Toronto, Ontario, Canada; University of Pittsburgh, Pittsburgh, Pennsylvania, USA; Royal Adelaide Hospital and University of Adelaide, Adelaide, Australia; University of Auckland, Auckland, New Zealand; Mayo Clinic, Rochester, Minnesota; National Jewish Hospital, Denver, Colorado, USA; Royal Brompton Hospital and National Heart and Lung Institute, London, UK; Scleroderma Research Consultants, Litchfield, Connecticut; Vibeke Strand, MD, Stanford University, Palo Alto, California, USA.D. Khanna, MD, MSc, Associate Professor of Medicine, Director, University of Michigan Scleroderma Program, University of Michigan; S. Mittoo, MD, MHS, University of Toronto; R. Aggarwal, MD, MS, Assistant Professor of Medicine, University of Pittsburgh; S.M. Proudman, MBBS, Royal Adelaide Hospital and Associate Professor Discipline of Medicine, University of Adelaide; N. Dalbeth, MD, FRACP, University of Auckland; E.L. Matteson, MD, Mayo Clinic; K. Brown, MD, National Jewish Hospital; K. Flahery, MD, MSc, Professor of Medicine, University of Michigan; A.U. Wells, MD, Royal Brompton Hospital and National Heart and Lung Institute; J.R. Seibold, MD, Scleroderma Research Consultants; V. Strand, MD, Stanford University.
Abstract
OBJECTIVE: Interstitial lung disease (ILD) is common in connective tissue disease (CTD) and is the leading cause of mortality. Investigators have used certain outcome measures in randomized controlled trials (RCT) in CTD-ILD, but the lack of a systematically developed, CTD-specific index that captures all measures relevant and meaningful to patients with CTD-ILD has left a large and conspicuous gap in CTD-ILD research. METHODS: The CTD-ILD working group, under the aegis of the Outcome Measures in Rheumatology (OMERACT) initiative, has completed a consensus group exercise to reach harmony on core domains and items for inclusion in RCT in CTD-ILD. During the OMERACT 12 meeting, consensus was sought on domains and core items for inclusion in RCT. In addition, consensus was pursued on a definition of response in RCT. Consensus was defined as ≥ 75% agreement among the participants. RESULTS: OMERACT 12 participants endorsed the domains with minimal modifications. Clinically meaningful progression for CTD-ILD was proposed as ≥ 10% relative decline in forced vital capacity (FVC) or ≥ 5% to < 10% relative decline in FVC and ≥ 15% relative decline in DLCO. CONCLUSION: There is consensus on domains for inclusion in RCT in CTD-ILD and on a definition of clinically meaningful progression. Data-driven approaches to validate these results in different cohorts and RCT are needed.
OBJECTIVE:Interstitial lung disease (ILD) is common in connective tissue disease (CTD) and is the leading cause of mortality. Investigators have used certain outcome measures in randomized controlled trials (RCT) in CTD-ILD, but the lack of a systematically developed, CTD-specific index that captures all measures relevant and meaningful to patients with CTD-ILD has left a large and conspicuous gap in CTD-ILD research. METHODS: The CTD-ILD working group, under the aegis of the Outcome Measures in Rheumatology (OMERACT) initiative, has completed a consensus group exercise to reach harmony on core domains and items for inclusion in RCT in CTD-ILD. During the OMERACT 12 meeting, consensus was sought on domains and core items for inclusion in RCT. In addition, consensus was pursued on a definition of response in RCT. Consensus was defined as ≥ 75% agreement among the participants. RESULTS: OMERACT 12 participants endorsed the domains with minimal modifications. Clinically meaningful progression for CTD-ILD was proposed as ≥ 10% relative decline in forced vital capacity (FVC) or ≥ 5% to < 10% relative decline in FVC and ≥ 15% relative decline in DLCO. CONCLUSION: There is consensus on domains for inclusion in RCT in CTD-ILD and on a definition of clinically meaningful progression. Data-driven approaches to validate these results in different cohorts and RCT are needed.
Authors: J R Seibold; C P Denton; D E Furst; L Guillevin; L J Rubin; A Wells; M Matucci Cerinic; G Riemekasten; P Emery; H Chadha-Boreham; P Charef; S Roux; C M Black Journal: Arthritis Rheum Date: 2010-07
Authors: Donald P Tashkin; Robert Elashoff; Philip J Clements; Jonathan Goldin; Michael D Roth; Daniel E Furst; Edgar Arriola; Richard Silver; Charlie Strange; Marcy Bolster; James R Seibold; David J Riley; Vivien M Hsu; John Varga; Dean E Schraufnagel; Arthur Theodore; Robert Simms; Robert Wise; Fredrick Wigley; Barbara White; Virginia Steen; Charles Read; Maureen Mayes; Ed Parsley; Kamal Mubarak; M Kari Connolly; Jeffrey Golden; Mitchell Olman; Barri Fessler; Naomi Rothfield; Mark Metersky Journal: N Engl J Med Date: 2006-06-22 Impact factor: 91.245
Authors: Talmadge E King; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Roland M du Bois; Jonathan A Leff; Steven D Nathan; Steven A Sahn; Dominique Valeyre; Paul W Noble Journal: Am J Respir Crit Care Med Date: 2014-04-01 Impact factor: 21.405
Authors: Maarten Boers; John R Kirwan; George Wells; Dorcas Beaton; Laure Gossec; Maria-Antonietta d'Agostino; Philip G Conaghan; Clifton O Bingham; Peter Brooks; Robert Landewé; Lyn March; Lee S Simon; Jasvinder A Singh; Vibeke Strand; Peter Tugwell Journal: J Clin Epidemiol Date: 2014-02-28 Impact factor: 6.437
Authors: Donald P Tashkin; Robert Elashoff; Philip J Clements; Michael D Roth; Daniel E Furst; Richard M Silver; Jonathan Goldin; Edgar Arriola; Charlie Strange; Marcy B Bolster; James R Seibold; David J Riley; Vivien M Hsu; John Varga; Dean Schraufnagel; Arthur Theodore; Robert Simms; Robert Wise; Fred Wigley; Barbara White; Virginia Steen; Charles Read; Maureen Mayes; Ed Parsley; Kamal Mubarak; M Kari Connolly; Jeffrey Golden; Mitchell Olman; Barri Fessler; Naomi Rothfield; Mark Metersky; Dinesh Khanna; Ning Li; Gang Li Journal: Am J Respir Crit Care Med Date: 2007-08-23 Impact factor: 21.405
Authors: Tiffany A Winstone; Deborah Assayag; Pearce G Wilcox; James V Dunne; Cameron J Hague; Jonathon Leipsic; Harold R Collard; Christopher J Ryerson Journal: Chest Date: 2014-08 Impact factor: 9.410
Authors: Shikha Mittoo; Sid Frankel; Daphne LeSage; Vibeke Strand; Ami A Shah; Lisa Christopher-Stine; Sonye Danoff; Laura K Hummers; Jeffery J Swigris; Dörte Huscher; Angela M Christensen; Sophia L Cenac; Jen K Erbil; Sancia Ferguson; Ignacio Garcia-Valladares; Harmanjot K Grewal; Ana-Maria Orbai; Katherine Clegg Smith; Maithy Tran; Clifton O Bingham; Flavia V Castelino; Aryeh Fischer; Lesley Ann Saketkoo Journal: Curr Respir Med Rev Date: 2015-06
Authors: Lesley Ann Saketkoo; Shikha Mittoo; Dörte Huscher; Dinesh Khanna; Paul F Dellaripa; Oliver Distler; Kevin R Flaherty; Sid Frankel; Chester V Oddis; Christopher P Denton; Aryeh Fischer; Otylia M Kowal-Bielecka; Daphne LeSage; Peter A Merkel; Kristine Phillips; David Pittrow; Jeffrey Swigris; Katerina Antoniou; Robert P Baughman; Flavia V Castelino; Romy B Christmann; Lisa Christopher-Stine; Harold R Collard; Vincent Cottin; Sonye Danoff; Kristin B Highland; Laura Hummers; Ami A Shah; Dong Soon Kim; David A Lynch; Frederick W Miller; Susanna M Proudman; Luca Richeldi; Jay H Ryu; Nora Sandorfi; Catherine Sarver; Athol U Wells; Vibeke Strand; Eric L Matteson; Kevin K Brown; James R Seibold Journal: Thorax Date: 2013-12-24 Impact factor: 9.139
Authors: Ayodeji Adegunsoye; Justin M Oldham; Jonathan H Chung; Steven M Montner; Cathryn Lee; Leah J Witt; Danielle Stahlbaum; Rene S Bermea; Lena W Chen; Scully Hsu; Aliya N Husain; Imre Noth; Rekha Vij; Mary E Strek; Matthew Churpek Journal: Chest Date: 2017-09-28 Impact factor: 9.410
Authors: Dinesh Khanna; James Seibold; Jonathan Goldin; Donald P Tashkin; Daniel E Furst; Athol Wells Journal: Rheumatology (Oxford) Date: 2017-09-01 Impact factor: 7.580